Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
NRx Pharmaceuticals (Nasdaq: NRXP) has announced the election of H.R. McMaster, retired Lieutenant General and former National Security Advisor, to its Board of Directors, effective May 27, 2021. McMaster's extensive military background and his current roles at Stanford University position him to contribute to NRx’s mission of accelerating therapies for patients with critical illnesses. The company also plans to seek Emergency Use Authorization for treatments related to Covid-19 and is advancing NRX-101 for suicidal bipolar depression, currently in Phase 3 trials.
NRx Pharmaceuticals (Nasdaq: NRXP) has signed a master services agreement with Cromos Pharma to conduct phase 3 clinical trials for COVID-19 treatments in Central Europe and the Caucasus Region. This initiative targets a population of over 500 million, many of whom lack access to effective treatments. Aimed at reducing hospitalization rates, NRx plans to complete trials for its inhaled drug, ZYESAMI™, by September 2021. The collaboration involves significant regional healthcare authorities and aims to address critical healthcare needs following discussions with government officials.
On May 25, 2021, NeuroRx announced its successful merger with Big Rock Partners Acquisition Corp., resulting in the formation of NRx Pharmaceuticals, Inc. The new entity will trade on the Nasdaq under the symbol NRXP. The company plans to use the public capital to advance the development of two investigational drugs: ZYESAMI™ for COVID-19 related respiratory failure and NRX-101 for suicidal bipolar depression. Both drugs are currently in FDA-approved Phase 3 trials. NRx aims to seek Emergency Use Authorization for ZYESAMI™ in May 2021.